AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Elevance Adds Former Cencora CEO Steve Collis to Board Amid Pharmacy Services Growth
ByAinvest
Thursday, Jul 31, 2025 3:10 pm ET1min read
Elevance Health has named Steve Collis, former CEO of Cencora, to its board of directors. Collis has three decades of experience in the drug distribution industry and will serve on Elevance's audit and finance committees. His expertise is expected to be valuable for Elevance's Carelon health services division, which includes pharmacy benefits manager CarelonRx. The division's revenue was up 20% in Q2, while operating profit rose 8%. Elevance plans to continue investing in growth.
Elevance Health (NYSE: ELV) has announced the addition of Steve Collis to its board of directors, effective August 1. Collis, a seasoned global healthcare executive, brings three decades of experience in the drug distribution industry. He will serve on the Audit and Finance Committees, enhancing Elevance's financial oversight capabilities [1].Collis is currently the Executive Chairman of Cencora (formerly AmerisourceBergen), where he has held several key executive leadership positions. Notably, he served as President and CEO from 2011 to 2024, leading significant strategic transformations. His appointment to Elevance Health reflects the company's commitment to board evolution and sound governance [1].
Elevance Health's Carelon health services division, which includes pharmacy benefits manager CarelonRx, is expected to benefit from Collis's expertise. The division's revenue grew by 20% in Q2 2025, while operating profit rose by 8%. Elevance plans to continue investing in growth [1].
Ramey Peru, Chair of the Elevance Health Board of Directors, stated, "Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on delivering high-quality care, driving innovation, and creating enduring value for the people and communities we serve" [1].
References:
[1] https://www.elevancehealth.com/newsroom/elevance-health-board-welcomes-steve-collis-as-new-director
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet